APA (7th ed.) Citation

Fadlalla, A., Makki, A. A., Ibraheem, W., Abdelrhman, M., Alzain, A. A., Ashour, A., . . . El-Sakhawy, M. A. (2026). Macitentan as a repurposed MCL-1 inhibitor in triple-negative breast cancer: Insights from molecular docking, MM-GBSA, and MD simulations. Journal of King Saud University - Science, 38(5), 1. https://doi.org/10.25259/JKSUS_1725_2025

Chicago Style (17th ed.) Citation

Fadlalla, Abdalla, et al. "Macitentan as a Repurposed MCL-1 Inhibitor in Triple-negative Breast Cancer: Insights from Molecular Docking, MM-GBSA, and MD Simulations." Journal of King Saud University - Science 38, no. 5 (2026): 1. https://doi.org/10.25259/JKSUS_1725_2025.

MLA (9th ed.) Citation

Fadlalla, Abdalla, et al. "Macitentan as a Repurposed MCL-1 Inhibitor in Triple-negative Breast Cancer: Insights from Molecular Docking, MM-GBSA, and MD Simulations." Journal of King Saud University - Science, vol. 38, no. 5, 2026, p. 1, https://doi.org/10.25259/JKSUS_1725_2025.